Jenkem Technology announced that the Phase III clinical trial of injection polyethylene glycol irinotecan developed independently by its wholly-owned subsidiary Tianjin Jenkem Technology Co., Ltd. for the treatment of small cell lung cancer, titled "Phase III Clinical Study of JK1201I for Recurrent or Progressive Extensive-Stage Small Cell Lung Cancer," has recently completed the enrollment of the first subject. Polyethylene glycol irinotecan is a small molecule long-acting anti-cancer innovative drug independently developed by the company, and obtained the clinical trial approval in January 2016.